Cargando…
The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice
RATIONALE: Using the drinking-in-the-dark (DID) model, we compared the effects of a novel mu-opioid receptor antagonist, GSK1521498, with naltrexone, a licensed treatment of alcohol dependence, on ethanol consumption in mice. OBJECTIVE: We test the ability of GSK1521498 to reduce alcohol consumption...
Autores principales: | Ripley, Tamzin L., Sanchez-Roige, Sandra, Bullmore, Edward T., Mugnaini, Manolo, Maltby, Kay, Miller, Sam R., Wille, David R., Nathan, Pradeep, Stephens, David N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537503/ https://www.ncbi.nlm.nih.gov/pubmed/26141191 http://dx.doi.org/10.1007/s00213-015-3995-x |
Ejemplares similares
-
The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects
por: Ziauddeen, Hisham, et al.
Publicado: (2013) -
Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects
por: Ziauddeen, H, et al.
Publicado: (2013) -
Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects
por: Ziauddeen, H, et al.
Publicado: (2014) -
The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours
por: Kelly, Eamonn, et al.
Publicado: (2014) -
Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype
por: Ziauddeen, Hisham, et al.
Publicado: (2016)